Bionomics, an Australian Phase 2 biotech developing allosteric ion channel modulators for CNS disorders, filed for an initial public offering up to $25M with the U.S. Securities and Exchange Commission.
The company's shares currently trade on the Australian Securities Exchange under the symbol BNO.
The company plans to offer American depositary shares on the Nasdaq Global Market under the symbol BNOX.
Bionomics is developing novel, allosteric ion channel modulators for patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. The company is advancing its lead candidate, BNC210, an oral proprietary selective negative allosteric modulators of the α7 receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD).
It expects to initiate its Phase 2 PREVAIL trial of BNC210 for SAD by the end of 2021, with topline data anticipated by the end of 2022, and has initiated its Phase 2b ATTUNE trial of BNC210 for PTSD, with topline data anticipated in the 1H23.
Evercore ISI, William Blair, and Cantor Fitzgerald are the joint bookrunners on the deal.
No pricing terms were disclosed.